Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Waters, Prosolia Exclusive Agreement for DESI Technology for Clinical MS Applications

Published: Monday, June 16, 2014
Last Updated: Tuesday, June 17, 2014
Bookmark and Share
Prosolia DESI Technology now available on SYNAPT G2 Si and Xevo G2-XS QTof mass spectrometers.

Waters Corporation has signed an agreement with Prosolia, Inc. (Indianapolis, IN) for the exclusive rights to DESI (Desorption Electrospray Ionization) technology for clinical research applications for use with Waters®  time-of-flight mass spectrometers, including its SYNAPT® G2 Si and Xevo® G2-XS QTof mass spectrometers. The announcement came at the 62nd conference of the American Society of Mass Spectrometry (ASMS).

When used for clinical research studies, DESI is a non-destructive means by which researchers using mass spectrometry can determine, with specificity and speed, the molecular distributions of drugs, lipids and metabolites from human tissue samples. Otherwise known as in vitro “tissue imaging”, it allows scientists to potentially distinguish healthy tissue from diseased tissue.

“By combining Prosolia’s DESI with Waters' time-of-flight mass spectrometers, we see the potential to advance clinical research in meaningful ways,” said Dr. Rohit Khanna, Vice President of Worldwide Marketing and Informatics for the Waters Division. “This agreement with Prosolia is an important step in fulfilling our vision of improving human health by partnering with the biomedical community to make breakthrough scientific discoveries and translate them into healthcare solutions.”

A bottleneck in life science research is the time and expertise required for sample preparation. Tissue sample preparation can be a tedious process that often involves multiple steps, delaying the time to a result, decreasing productivity and increasing the probability for error. DESI eliminates this bottleneck by enabling direct, automated analysis of tissue samples thereby reducing the requirement for extensive sample preparation and enabling high throughput sample analysis. These capabilities translate into lower laboratory operational costs, streamlined workflows and generate results faster than traditional approaches.

“Waters is a natural choice for Prosolia to partner with to advance the DESI technology in the clinical research space,” said Dr. Justin Wiseman, Chairman, President & CEO of Prosolia. “Waters’ mass spectrometry technology and vision of a healthier future for humanity appealed to us on many levels and we are looking forward to a long and successful relationship.”

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More Than 5,200+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Waters Announces New Reference Library for Metabolite Profiling by Ion Mobility Separations
Company has Introduced a new metabolic profiling reference library for use during ion mobility at the 64th American Society for Mass Spectrometry (ASMS) meeting.
Thursday, June 09, 2016
It is All About the Product, Right?
Technology Networks met with Waters Corporation at its head office in Milford, MA to better understand the factors they use to drive business success.
Monday, January 11, 2016
R&D 100 Award Goes to Waters ionKey/MS System
Novel approach is enhancing the sensitivity of bioanalytical, biomarker validation, pharmacokinetic and food research LC/MS analyses.
Thursday, November 26, 2015
SIMM Honored by Waters Centers of Innovation Program
Research Center for traditional Chinese medicine modernization recognized for advancing quality control authentication and profiling methods.
Wednesday, October 28, 2015
Waters’ Centers of Innovation Program Honors Ohio State University Laboratory
Wysocki-led facility recognized for proteomics, disease research and mass spectrometry excellence.
Wednesday, September 23, 2015
Waters Corporation Announces Christopher J. O'Connell as CEO
Chris joins Waters® from Medtronic plc.
Thursday, July 02, 2015
Waters Centers of Innovation Program Honors CSU Laboratory
Proteomics and metabolomics facility recognized for innovation in biological mass spectrometry.
Wednesday, October 29, 2014
Waters Q3 Revenues up 8 Percent
Company reports third quarter sales of $493 million, an increase of 8% versus sales of $457 million in the third quarter of 2013.
Tuesday, October 21, 2014
Waters, Chinese Pharmacopeia Commission Establish Joint Open Laboratory
Located in the laboratory building of Beijing Zhendong Guangming Drug Research Institute, the new facility is over 400m2.
Thursday, July 10, 2014
New Solutions to Old Challenges
Waters Corporation introduces a new NuGenesis Lab Management System (LMS) that integrates sample management functions and business operations across the enterprise. Technology Networks' Editor Helen Gillespie interviewed Waters' Garrett Mullen for details.
Tuesday, July 01, 2014
Waters, Omics LLC Partner to Advance Petroleum Sample Analysis
Collaboration Combines the Value of Ion Mobility Mass Spectrometry (IM-MS) and Accurate Mass Information with Petroleomics Data Processing.
Monday, June 16, 2014
Waters ACQUITY UPLC TQD System Receives Chinese FDA Approval
Chinese FDA approves ACQUITY UPLC TQD system for routine diagnostic applications and neonatal metabolites diseases screening.
Thursday, June 05, 2014
Waters ACQUITY QDa Detector Takes Pittcon Editors' Award
Product receives Editors' Silver award for the most innovative product introduced at Pittcon 2014.
Monday, March 10, 2014
Waters Report 8% Revenue Increase
Fourth quarter 2013 sales were $565 million, an increase of 8% compared to sales of $522 million in the fourth quarter of 2012.
Tuesday, January 28, 2014
Waters Teams With Biochemical Society on Proteomics Training Day and Symposium
The consecutive events will take place on March 24 - 27, 2014 in Chester, England.
Wednesday, November 27, 2013
Scientific News
Integrated Omics Analysis
Studying multi-omics promises to give a more holistic picture of the organism and its place in its ecosystem, however despite the complexities involved those within the field are optimistic.
Unravelling the Role of Key Genes and DNA Methylation in Blood Cell Malignancies
Researchers from the University of Nebraska Medical Center have demonstrated the role of Dnmt3a in safeguarding normal haematopoiesis.
Salford Lung Study - The First Real World Clinical Trial
In this podcast, we learn about the Salford Lung Study and its potential to revolutionize the way we assess new drugs and treatments around the world.
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
Zika Virus Infection Alters Human and Viral RNA
Researchers have discovered that Zika infections results in human and viral genetic modification.
RNA-Binding Proteins Role in ALS Revealed
Researchers describe how damage to RNA-binding protein contributes to ALS, isolating a possible therapeutic target.
MRIs for Fetal Health
Algorithm could help analyze fetal scans to determine whether interventions are warranted.
Illumina Contributes to ClinVar Database
The contribution includes variants of all classifications, from pathogenic to benign, identified during interpretation of whole genome sequences generated in the CLIA-certified, CAP-accredited Illumina Clinical Services Laboratory.
Structure of Primary Cannabinoid Receptor is Revealed
The findings provide key insights into how natural and synthetic cannabinoids including tetrahydrocannabinol —a primary chemical in marijuana—bind at the CB1 receptor to produce their effects.
Overlooked Molecules Could Revolutionise our Understanding of the Immune System
Researchers have discovered that around one third of all the epitopes displayed for scanning by the immune system are a type known as ‘spliced’ epitopes.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,200+ scientific videos